Need help finding what you are looking for?
Contact Us
PUBLISHER: BCC Research | PRODUCT CODE: 1385519
PUBLISHER: BCC Research | PRODUCT CODE: 1385519
Melanoma Therapeutics: Global Markets
PUBLISHED:
PAGES: 131 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
Highlights:
The global market for melanoma therapeutics is estimated to increase from $7.4 billion in 2023 to reach $12.1 billion by 2028, at a compound annual growth rate (CAGR) of 10.2% from 2023 through 2028.
North American market for melanoma therapeutics is estimated to increase from $3.5 billion in 2023 to reach $5.8 billion by 2028, at a compound annual growth rate (CAGR) of 11.0% from 2023 through 2028.
European market for melanoma therapeutics is estimated to increase from $2.3 billion in 2023 to reach $3.8 billion by 2028, at a compound annual growth rate (CAGR) of 10.1% from 2023 through 2028.
Report Scope:
This study investigates the melanoma treatment market. BCC Research analyzes melanoma treatment based on treatment type, cancer stage and type of therapeutics. BCC determines the current market status in each segment, examines its impact on future needs and presents growth forecasts over the next five years. The report provides a detailed analysis of the market's drivers, challenges, and opportunities. The report also covers market projections through 2028 and analyzes market share for key market players. In its profiles of key companies, the report provides detailed information about their business segments, financials, product portfolios and recent developments. The report also discusses the market impact of the COVID-19 pandemic, emerging technologies, and new developments, ESG development and investment outlook.
Report Includes:
- 30 data tables and 18 additional tables
- An overview of the global market for melanoma treatment
- Analyses of global market trends, with data from 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
- Description of various treatment options such as chemotherapy, surgical resection, immunotherapy, and targeted therapies; and various treatment approaches for the betterment of patient's overall health
- A look at the advancements in the genetic profiling of melanocytes and identification of novel molecules that involved in melanoma's development
- Information on new potential therapeutic target discovery; and description of novel immune checkpoint inhibitors, adoptive cell therapy and engineered TCR therapy
- Coverage of innovation, technological advancements, and the launch of novel products from market players
- Detailed analysis of the regulatory framework and policies and product pipeline of the industry, and discussion on ESG challenges in the pharmaceutical industry and ESG practices in the melanoma treatment market
- Market share analysis of the key companies of the industry and coverage of their proprietary technologies, strategic alliances, and other key market strategies and a relevant patent analysis
- Comprehensive company profiles of the leading players of the industry, including Amgen, Roche, Merck & Co., Pfizer Inc., BMS, and Novartis AG
Product Code: PHM279A
Table of Contents
Chapter 1 Introduction
- Study Goals and Objectives
- Scope of the Report
- Reasons for Doing the Study
- Methodology
- Information Sources
- Geographic Breakdown
- Segmentation Breakdown
Chapter 2 Summary and Highlights
- Market Outlook
- Market Summary
Chapter 3 Market and Technology Background
- Introduction
- Risk Factors, Causes and Prevention
- Symptoms
- Pathophysiology and Clinical Subtypes
- Prognosis
- Epidemiology
- Diagnosis
- Biopsy
- Laboratory Tests
- Blood Tests
- Imaging Tests
- Treatment
- Immunotherapy
- PD-1 and PD-L1 Inhibitors
- CTLA-4 inhibitors
- LAG-3 Inhibitors
- Interleukin-2 (IL-2, Proleukin)
- Virus Therapy
- BRAF inhibitors:
- MEK Inhibitors
Chapter 4 Market Dynamics
- Market Factors
- Market Drivers
- Increasing Prevalence of Melanoma
- Technological Advancements and Product Launches
- Strategic Initiatives
- Developments in Early Detection Tools
- Patient Advocacy Groups and Awareness
- Market Restraints
- High Cost of Treatment
- Stringent Regulations
- Resistance to Therapies
- Market Opportunities
Chapter 5 Market Breakdown by Type
- Overview
- Surgery
- Wide Excision
- Mohs Surgery
- Amputation
- Lymph Node Dissection
- Therapeutics
- Therapeutics by Type
- Radiation Therapy
Chapter 6 Market Breakdown by Disease Stage
- Overview
- Localized Disease
- Regional Disease
- Distant Disease
Chapter 7 Market Breakdown by Region
- Overview
- North America
- Europe
- Asia-Pacific
- Rest of the World
Chapter 8 Sustainability: An ESG Perspective
- Introduction
- ESG Challenges in the Pharmaceutical Industry
- ESG Practices in the Market for Melanoma Therapeutics
- Environmental Initiatives
- Social Initiatives
- Governance Initiatives
- Case Study
- BCC Research Viewpoint
Chapter 9 Emerging Technologies/ Developments
- Introduction
- Novel Immune Checkpoint Inhibitors
- Adoptive Cell Therapy
- Engineered TCR Therapy
- Vaccines
- Targeted Therapy
Chapter 10 Regulatory Landscape and Pipeline Analysis
- Regulatory Landscape
- United States
- Europe
- Japan
- Pipeline Analysis
Chapter 11 Patent Analysis
- Patent Review by Year
- Patent Review by Country
- Patent Review
Chapter 12 Competitive Landscape
- Mergers and Acquisitions
- Strategic Initiatives
- Competitive Analysis
Chapter 13 Company Profiles
- AMGEN INC.
- ASTRAZENECA PLC
- BRISTOL-MYERS SQUIBB
- ERASCA INC.
- F. HOFFMANN-LA ROCHE AG
- HUYABIO INTERNATIONAL
- IOVANCE BIOTHERAPEUTICS INC.
- IO BIOTECH
- MERCK & CO. INC.
- MODERNA INC.
- NOVARTIS AG
- PFIZER INC.
- REGENERON PHARMACEUTICALS INC.
Product Code: PHM279A
List of Tables
- Summary Table A : Global Market for Melanoma Therapeutics, Through 2028
- Summary Table B : Global Market for Melanoma Therapeutics, by Region, Through 2028 ($ Millions)
- Table 1 : List of Approved Therapies for Melanoma
- Table 2 : Global Melanoma Cancer Statistics, by WHO Region, 2020
- Table 3 : Global Market for Melanoma Therapeutics, by Type, Through 2028
- Table 4 : Recommended Margins for Surgical Excision
- Table 5 : Global Market for Surgical Treatment of Melanoma, by Region, Through 2028
- Table 6 : Global Market for Melanoma Therapeutics, by Region, Through 2028
- Table 7 : Global Market for Melanoma Therapeutics, by Type, Through 2028
- Table 8 : Global Market for Melanoma Therapeutics for Immunotherapy, by Region, Through 2028
- Table 9 : Global Market for Melanoma Targeted Therapies, by Region, Through 2028
- Table 10 : Global Market for Melanoma Chemotherapy, by Region, Through 2028
- Table 11 : Global Market for Melanoma Radiation Therapy, by Region, Through 2028
- Table 12 : Estimated Costs per Person Diagnosed with Melanoma Over a 5-Year Period, by Disease Stage, 2020
- Table 13 : Global Market for Melanoma Therapeutics, by Disease Stage, Through 2028
- Table 14 : Global Market for Melanoma Therapeutics for Localized Disease Stage, by Region, Through 2028
- Table 15 : Global Market for Melanoma Therapeutics for the Regional Disease Stage, by Region, Through 2028
- Table 16 : Global Market for Melanoma Therapeutics for the Distant Metastasis Stage, by Region, Through 2028
- Table 17 : Global Market for Melanoma Therapeutics, by Region, Through 2028
- Table 18 : North American Market for Melanoma Therapeutics, by Country, Through 2028
- Table 19 : European Market for Melanoma Therapeutics, by Country, Through 2028
- Table 20 : Estimated Incidence, Mortality and Prevalence of Melanoma in 2020
- Table 21 : Asia-Pacific Market for Melanoma Therapeutics, by Country, Through 2028
- Table 22 : Key ESG Issues in the Pharmaceutical Industry
- Table 23 : Environmental Initiatives by Various Melanoma Therapeutics Companies
- Table 24 : ESG Rankings for Companies in the Market for Melanoma Therapeutics for 2023
- Table 25 : Industry-Leading Performance Across Priority ESG Ratings
- Table 26 : Melanoma Pipeline: Phase II and Phase III Clinical Trials
- Table 27 : Patents Issued on Melanoma Therapeutics, by Year, January 2020-August 2023
- Table 28 : Patents Issued for Melanoma Therapeutics, by Country, 2020-August 2023
- Table 29 : Patents Issued on Melanoma Therapeutics, by Applicant, 2020-August 2023
- Table 30 : Mergers and Acquisitions, 2020-2023
- Table 31 : Amgen: Financials, 2021 and 2022
- Table 32 : Amgen: Marketed Products
- Table 33 : BMS: Financials, 2021 and 2022
- Table 34 : BMS: Marketed Products
- Table 35 : BMS: News, 2019-2023
- Table 36 : Roche: Financials, 2021 and 2022
- Table 37 : Roche: Marketed Products
- Table 38 : Roche: News, 2022
- Table 39 : Merck & Co.: Financials, 2021 and 2022
- Table 40 : Merck & Co.: Marketed Products
- Table 41 : Merck & Co.: News, 2021-2023
- Table 42 : Novartis AG: Financials, 2021 and 2022
- Table 43 : Novartis AG: Marketed Products
- Table 44 : Pfizer Inc.: Financials, 2021 and 2022
- Table 45 : Pfizer Inc.: Marketed Products
- Table 46 : Pfizer Inc.: News, 2021-2023
List of Figures
- Summary Figure A : Global Market for Melanoma Therapeutics, 2020-2028
- Summary Figure B : Global Market for Melanoma Therapeutics, by Region, 2020-2028
- Figure 1 : Schematic Diagram of Skin Structure
- Figure 2 : ABCDE Rule for Melanoma
- Figure 3 : Melanoma Staging
- Figure 4 : Melanoma by Stages
- Figure 5 : Estimated Number of New Skin Melanoma Cases Worldwide for Both Sexes, by Age Group, 2020
- Figure 6 : Melanoma Therapeutics Algorithm
- Figure 7 : Global Market for Melanoma Therapeutics, by Type, 2020-2028
- Figure 8 : Global Market Shares of Melanoma Therapeutics, by Type, 2022
- Figure 9 : Global Market for Surgical Treatment of Melanoma, by Region, 2020-2028
- Figure 10 : Timeline of FDA Treatment Approvals in Melanoma
- Figure 11 : Global Market for Melanoma Therapeutics, by Region, 2020-2028
- Figure 12 : Global Market for Melanoma Therapeutics, by Type, 2020-2028
- Figure 13 : Global Market Shares of Melanoma Therapeutics, by Type, 2022
- Figure 14 : Global Market for Melanoma Therapeutics for Immunotherapy, by Region, 2020-2028
- Figure 15 : Global Market for Melanoma Targeted Therapies, by Region, 2020-2028
- Figure 16 : Global Market for Melanoma Chemotherapy, by Region, 2020-2028
- Figure 17 : Global Market for Melanoma Radiation Therapy, by Region, 2020-2028
- Figure 18 : Global Market for Melanoma Therapeutics, by Disease Stage, 2020-2028
- Figure 19 : Global Market Shares of Melanoma Therapeutics, by Disease Stage, 2022
- Figure 20 : Global Market for Melanoma Therapeutics for Localized Disease Stage, by Region, 2020-2028
- Figure 21 : Global Market for Melanoma Therapeutics for the Regional Disease Stage, by Region, 2020-2028
- Figure 22 : Global Market for Melanoma Therapeutics for the Distant Metastasis Stage, by Region, 2020-2028
- Figure 23 : Global Market for Melanoma Therapeutics, by Region, 2020-2028
- Figure 24 : Global Market Shares of Melanoma Therapeutics, by Region, 2022
- Figure 25 : North American Market for Melanoma Therapeutics, by Country, 2020-2028
- Figure 26 : European Market for Melanoma Therapeutics, by Country, 2020-2028
- Figure 27 : Asia-Pacific Market for Melanoma Therapeutics, by Country, 2020-2028
- Figure 28 : RoW Market for Melanoma Therapeutics, 2020-2028
- Figure 29 : ESG in Market for Melanoma Therapeutics
- Figure 30 : Novartis ESG Analysis
- Figure 31 : Clinical Trial Analysis
- Figure 32 : Shares of Patents Issued on Melanoma Therapeutics, by Year, January 2020 to August 2023
- Figure 33 : Global Market Shares of Melanoma Therapeutics, by Company, 2022
- Figure 34 : Amgen: Financials, 2021 and 2022
- Figure 35 : Amgen: Revenue Share, by Country/Region, 2022
- Figure 36 : BMS: Financials, 2021 and 2022
- Figure 37 : BMS: Revenue Share, by Business Unit, 2022
- Figure 38 : BMS: Revenue Share, by Country/Region, 2022
- Figure 39 : Roche: Annual Revenue, 2021 and 2022
- Figure 40 : Roche: Revenue Share, by Business Unit, 2022
- Figure 41 : Roche: Revenue Share, by Region, 2022
- Figure 42 : Merck & Co.: Financials, 2021 and 2022
- Figure 43 : Merck & Co.: Revenue Share, by Business Unit, 2022
- Figure 44 : Merck & Co.: Revenue Share, by Country/Region, 2022
- Figure 45 : Novartis AG: Financials, 2021 and 2022
- Figure 46 : Novartis AG: Revenue Share, by Business Unit, 2022
- Figure 47 : Novartis AG: Revenue Share, by Region, 2022
- Figure 48 : Pfizer Inc.: Financials, 2021 and 2022
- Figure 49 : Pfizer Inc.: Revenue Share, by Business Unit, 2022
- Figure 50 : Pfizer Inc.: Revenue Share, by Region, 2022
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.